Contact Harry Rowland
Title CEO


Summary: Endotronix, Inc., a medical technology company, has developed an integrated platform to provide comprehensive, reimbursable health management innovations for patients suffering from heart failure (HF). The company’s solution, the Cordella™ Heart Failure System, includes a cloud-based disease management data system and at-home hemodynamic management with a breakthrough implantable wireless pulmonary artery (PA) pressure sensor for early detection of worsening HF. Disease management with PA pressure has delivered meaningful clinical outcomes including, a reduction in HF hospitalizations and mortality. The Cordella System engages patients by reminding them, daily, to collect physiologic data, as well as symptoms and general health status, and transmits the information to the HF cardiologists’ clinic. The clinic is able to view the information in an intuitive portal that aligns with existing workflows enabling succinct patient management with real-time information. The portal is also able to leverage data insights to enable the clinic to better medically manage the patients without requiring a clinic visit for physiologic monitoring to achieve guideline-directed medical therapy. The patient is encouraged to engage in their own care by providing them with trends of their own care by providing them with trends of their own health information.
Need: Heart failure (HF) is the number one cost to Medicare, comprising ~$40B for the treatment of HF, 70% of which is related to HF hospitalizations. Additionally, patients with a HF diagnosis have a 50% mortality rate at 5 years and a significantly lower quality of life.
Value: Endotronix has developed heart failure solutions focused on improving outcomes for heart failure patients, creating therapeutic best practices and streamlining high-quality reimbursable care management. We provide the tools for clinicians to provide proactive care, improving the patients’ quality of life and strengthening communication between the patient and clinic.

Company News

Endotronix Celebrates 100th Implant Of The Cordella Pulmonary Artery Pressure Sensor For Proactive, Remote Management Of Heart Failure

DateMar 23, 2021
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced the 100th global implant of the Cordella Pulmonary Artery Pressure Sensor (Cordella Sensor) by Cardiologist and top worldwide implanter Faisal Sharif, MD of Bon Secours Hospital and Director of Cardiovascular Research at NUIG, both in Galway, Ireland.
Read More →

Western Ireland’s University Hospital Galway Leading Advanced Heart Failure Monitoring Clinical Trial

DateJun 6, 2020
The investigational product, known as the Cordella Sensor from U.S.-based company called Endotronix, detects changes in the health of patients with heart failure while securely transmitting information to the cardiovascular team. With this data in real time, the cardiovascular team can not only receive relevant updates but also can intervene with the goal of preventing heart failure flare-up resulting in emergency hospitalization.
Read More →

Endotronix begins heart failure study with Cordella Sensor

DateFeb 19, 2020
Digital health and medical technology firm Endotronix has recruited the first two patients in the PROACTIVE-HF pivotal trial of the Cordella pulmonary artery (PA) pressure sensor system.
Read More →